Drugs in Dev. Infections and Infectious Diseases
Phase I
Singapore 
Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The spike-protein component of ACM-001 is modeled after the immune-evasive beta variant. In animal studies the clinical vaccine candidate was safe and generated a protective immune response against the beta-variant and ancestral form of SARS-2.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACM-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : ACM-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Temasek-backed Tychan to Start Human Trials Next Week for COVID-19 Treatment
Details : The study to be conducted by Tychan is meant to determine the safety and effectiveness of TY027, a monoclonal antibody or immune system protein that specifically targets Sars-CoV-2, the virus that causes Covid-19.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TY014
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NEJM Study Demonstrates Safety and Efficacy of mAb to Treat Yellow Fever
Details : Data published in the New England Journal of Medicine demonstrate that TY014 was not only safe and well tolerated at the highest doses tested, but also completely eradicated the yellow fever virus in the bloodstream of all participants within 48 hours of...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 30, 2020
Lead Product(s) : TY014
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of TY027, a Treatment for COVID-19, in Humans
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 12, 2020
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tyzivumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Singapore Clinical Research Institute | Duke-NUS Graduate Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 17, 2018
Lead Product(s) : Tyzivumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Singapore Clinical Research Institute | Duke-NUS Graduate Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tyzivumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Duke-NUS Graduate Medical School | Singapore Clinical Research Institute | National University of Singapore | National University Hospital, Singapore
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 23, 2018
Lead Product(s) : Tyzivumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Duke-NUS Graduate Medical School | Singapore Clinical Research Institute | National University of Singapore | National University Hospital, Singapore
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
